Valuation: Clene Inc.

Market Cap 7.79Cr 6.81Cr 6.26Cr 5.84Cr 11Cr 742.17Cr 11Cr 75Cr 29Cr 364.82Cr 29Cr 29Cr 1.26TCr P/E 2026 *
-3.42x
P/E 2027 * -4.14x
Enterprise Value 6.45Cr 5.64Cr 5.19Cr 4.83Cr 9.17Cr 614.58Cr 9.31Cr 62Cr 24Cr 302.1Cr 24Cr 24Cr 1.04TCr EV / Sales 2026 *
311x
EV / Sales 2027 * 2.39x
Free-Float
82.94%
Yield 2026 *
-
Yield 2027 * -
1 day-0.49%
1 week+5.35%
Current month-0.89%
1 month+3.92%
3 months+19.14%
6 months+5.72%
Current year+3.92%
1 week 6.03
Extreme 6.03
6.43
1 month 5.25
Extreme 5.25
6.46
Current year 3.88
Extreme 3.88
8.67
1 year 3.25
Extreme 3.25
13.5
3 years 2.28
Extreme 2.2801
17.6
5 years 2.28
Extreme 2.2801
356.4
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2013
Chief Tech/Sci/R&D Officer 67 01/01/2013
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 65 01/11/2015
Director/Board Member 53 01/09/2019
Director/Board Member 49 01/12/2020
Date Insider Type Main position Quantity % Market Cap.
11/06Free

Chief Financial Officer

15,000 0.1174%
11/06Free

Chief Executive Officer

65,000 0.5087%
11/06Free

Founder

45,000 0.3522%
Change 5-day change 1-year change 3-year change Capi.($)
-0.49%+5.35%+54.43%-65.34% 7.79Cr
+0.68%+5.92%+80.45%+137.78% 5.87TCr
+2.32%+5.89%+76.81%+99.20% 5.39TCr
-10.61%+8.38%-9.90%-9.62% 2.47TCr
-0.30%+6.82%+13.60%+428.91% 2.42TCr
+4.74%+13.47%+46.43%+0.03% 1.88TCr
-0.29%+9.78%+44.62%-27.94% 1.76TCr
0.00%+16.74%+171.12%+355.99% 1.63TCr
+3.50%+4.92%+26.07%+192.26% 1.4TCr
+6.72%+20.94%+51.67% - 1.39TCr
Average +2.53%+6.98%+55.53%+123.47% 2.42TCr
Weighted average by Cap. +2.44%+5.53%+59.79%+138.28%

Financials

2026 *2027 *
Net sales 2L 2L 2L 2L 3L 1.97Cr 3L 20L 8L 97.07L 8L 8L 3.34Cr 2.36Cr 2.07Cr 1.9Cr 1.77Cr 3.36Cr 225.13Cr 3.41Cr 23Cr 8.87Cr 110.66Cr 8.88Cr 8.68Cr 381.33Cr
Net income -2.51Cr -2.19Cr -2.02Cr -1.88Cr -3.56Cr -238.93Cr -3.62Cr -24Cr -9.41Cr -117.45Cr -9.42Cr -9.22Cr -404.71Cr -2.75Cr -2.41Cr -2.21Cr -2.06Cr -3.91Cr -262.29Cr -3.97Cr -27Cr -10Cr -128.93Cr -10Cr -10Cr -444.29Cr
Net Debt -1.34Cr -1.17Cr -1.08Cr -1Cr -1.9Cr -127.59Cr -1.93Cr -13Cr -5.02Cr -63Cr -5.03Cr -4.92Cr -216.11Cr -2.14Cr -1.87Cr -1.72Cr -1.6Cr -3.04Cr -203.76Cr -3.09Cr -21Cr -8.02Cr -100.16Cr -8.03Cr -7.86Cr -345.14Cr
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
78
Date Price Change Volume
02/26/02 $6.100 -0.49% 30,035
01/26/01 $6.130 -0.41% 37,996
30/26/30 $6.155 -2.84% 75,802
29/26/29 $6.335 +4.54% 1,06,316
26/26/26 $6.060 +4.66% 1,04,311
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.100USD
Average target price
32.20USD
Spread / Average Target
+427.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock